Logo

Biosimilars ... That's Catchy

Mar 17, 2007

An article from the Wall Street Journal earlier this week points out the growing controversy over how to deal with (and whether to allow) generic versions of biotech drugs. Biotech companies argue that there's no way to engineer and deliver a generic version without all the same safety testing and regulations that went into making the original, but that hasn’t stopped companies from starting work on it -- or legislators from proposing bills allowing for these kinds of generics.

 

Breaking News
The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.